From targeted therapy to a novel way: immunogenic cell death in lung cancer

HIGHLIGHTS

• who: Jiawei Xu from the National Institutes of Health (NIH), United States University of Padua, Italy have published the Article: From targeted therapy to a novel way: Immunogenic cell death in lung cancer, in the Journal: (JOURNAL)
• what: Accumulating evidence has elucidated that, although the acquired resistance mechanism varies, the main reasons are from three aspects: mutant gene modification, phenotypic transformation and alternative signal pathway activation .
• how: The results showed that EGFR signaling could govern MEK/ERK pathway more strongly however the situation is not the same in BRAFV600E mutant lung cancer which . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.